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SUMMARY
We describe a comprehensive genomic characterization of adrenocortical carcinoma (ACC). Using 
this dataset, we expand the catalogue of known ACC driver genes to include PRKAR1A, RPL22, 
TERF2, CCNE1, and NF1. Genome wide DNA copy number analysis revealed frequent 
occurrence of massive DNA loss followed by whole genome doubling (WGD) which was 
associated with aggressive clinical course, suggesting WGD is a hallmark of disease progression. 
Corroborating this hypothesis were increased TERT expression, decreased telomere length, and 
activation of cell cycle programs. Integrated subtype analysis identified three ACC subtypes with 
distinct clinical outcome and molecular alterations which could be captured by a 68 CpG probe 
DNA methylation signature, proposing a strategy for clinical stratification of patients based on 
molecular markers.
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Graphical Abstract
INTRODUCTION
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with an annual incidence of 
0.7–2 per million (Bilimoria et al., 2008; Else et al., 2014a). Current staging schemes such 
as by the European Network for the Study of Adrenal Tumors (ENSAT) broadly divides 
ACCs into 4 stages (Fassnacht et al., 2009). While stage I and II tumors are organ-confined 
and potentially curable by complete resection, advanced stage tumors are invasive (stage III) 
and/or metastatic (stage IV), with a dismal 5 year survival of 6–13% for stage IV patients 
(Else et al., 2014b; Fassnacht et al., 2009; Fassnacht et al., 2013). Histologic grading of 
ACC based on proliferation (Giordano, 2011; Weiss et al., 1989) refines treatment decisions 
for specific patient subgroups, but is not universally accepted (Miller et al., 2010). 
Chemotherapy, radiotherapy and the adrenolytic agent mitotane are the current standard 
therapeutic modalities for unresectable or metastatic ACC, but all are palliative (Else et al., 
2014a). Our understanding of ACC pathogenesis is incomplete and additional therapeutic 
avenues are needed.
Molecular studies have nominated several genes as potential drivers involved in sporadic 
adrenocortical tumorigenesis, including insulin-like growth factor 2 (IGF2), β-catenin 
(CTNNB1), and TP53 (Giordano et al., 2003; Tissier et al., 2005). β-catenin gain-of-function 
mutations are evident in approximately 25% of both benign and malignant sporadic 
adrenocortical neoplasms (Tissier et al., 2005). Recent genomic profiling efforts of ACC 
have identified candidate driver genes such as ZNRF3 and TERT, and identified molecular 
subgroups with variable clinical outcomes (Assie et al., 2014; Pinto et al., 2015). Germline 
variants of these genes are also associated with Beckwith-Wiedemann, Familial 
Adenomatous Polyposis Coli and Li-Fraumeni syndromes, in which adrenocortical 
neoplasia occur.
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Comprehensive and integrated genomic characterization of ACC may identify additional 
oncogenic alterations, provide a framework for further research, and guide development of 
therapies. As one of the rare cancer projects of The Cancer Genome Atlas (TCGA), we 
collected the clinical and pathological features, genomic alterations, DNA methylation 
profiles, and RNA and proteomic signatures of 91 cases of ACC. The comprehensive nature 
of the dataset combined with the many easy access routes to the individual and aggregated 
profiles will serve as a point of reference for many future ACC and comparative cancer 
studies. Here, we report this resource and an integrated analysis of the data.
RESULTS
Patient cohort, clinical annotation and analytical approach
We analyzed 91 histologically confirmed tumors and matched blood or normal tissue from a 
global cohort collected from 6 countries including 84 usual type, 4 oncocytic, 2 sarcomatoid 
and 1 myxoid variant. Median age at diagnosis was 49 years, and female:male ratio was 1.8. 
While 51 (56%) involved the left gland and 40 (44%) the right gland, more tumors in the left 
gland were diagnosed in males than females (72% vs 47%; p value=0.03, Fisher’s exact 
test). The majority of tumors (57%) were functional; hypercortisolism was the most 
common endocrinopathy. Resected tumors spanned all stages (stage I, n=9; II, n=43; III, 
n=19; IV, n=17; 3 unavailable). Median overall survival was 78 months with 5-year survival 
of 59%. Locally invasive and metastatic tumors (grade III plus IV) had dramatically reduced 
median overall survival (18 months) with 5-year survival of 22%. Clinicopathologic data are 
summarized in Table S1. Patient stage at diagnosis and cortisol hypersecretion were 
predictive for both overall survival and disease free survival (Else et al., 2014b), but age was 
only associated with overall survival. Gender had no clear association with disease stage or 
clinical outcome (Table S1).
We generated a comprehensive molecular dataset of the 91 tumors, as follows: whole exome 
sequence (n=90), mRNA sequence (n=78), miRNA sequence (n=79), DNA copy number via 
SNP arrays (n=89), DNA methylation via DNA methylation arrays (n=79) and targeted 
proteome from reverse phase protein array (RPPA; n=45) (Table S1).
Our analytical approach consisted of four main parts. We began by identifying somatic 
single nucleotide variants, gene fusions, and copy number alterations. Given the significant 
copy number alterations observed, we performed an extended bioinformatic analysis that 
revealed the role of genome doubling and telomere maintenance in ACC. Using the various 
molecular datasets, we derived molecular classifications of ACC and integrated a three class 
solution with the somatic genomic landscape. We placed ACC in the broader context of 
cancer by performing several pan-cancer analyses. Finally, we quantified adrenal 
differentiation and tumoral hormone production across the entire cohort to correlate the 
genomic results with clinical parameters. All unprocessed data used in the analysis can be 
accessed through the TCGA portals.
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Exome and RNA-sequencing nominate ACC driver events
Somatic single nucleotide variants (SSNVs) and small indels were detected using five 
independent mutation callers and variants called by at least three callers or independently 
validated by RNA sequencing were included (Figure S1A and S1B). This approach yielded a 
total of 8,814 high-confidence mutations (6,664 nonsynonymous and 2,150 synonymous; 
3,427 of these were found in two tumors with ultramutator phenotype. Deep coverage re-
sequencing (1,500×) achieved a validation rate of 95% (Supplemental Experimental 
Procedures and Table S1). The median somatic mutation density was 0.9 per Mb, similar to 
pancreatic adenocarcinoma but twice more than that of another endocrine tumor, papillary 
thyroid cancer (Figure S1C). Similar to other cancers, ACC demonstrated a marked 
heterogeneity in mutation density (range: 0.2 to 14.0 mutations/Mb, excluding the two 
ultramutators). Mutation density was correlated with numerous clinicopathological 
parameters including overall survival, time to recurrence, necrosis, stage, Weiss score, and 
mitotic count (Figure S1D). Interestingly, these associations remained when restricting to 
organ-confined stage I and II diseases.
We used MutSigCV (Lawrence et al., 2013) to identify five significantly mutated genes 
(SMGs): TP53, CTNNB1, MEN1, PRKAR1A and RPL22. The mutation frequencies ranged 
from 3.3% to 17.8% of the cohort (Figure 1A and Figure S1E). Mutations of TP53 and 
CTNNB1 in ACC are well recognized (Tissier et al., 2005). As expected, missense 
mutations in CTNNB1 were confined to exon 3 (Figure 1A). Six (7%) tumors harbored 
inactivating mutations in MEN1, consistent with prior studies implicating MEN1 in ACC 
(Assie et al., 2014). While our cohort is the largest to be sequenced to date, a much larger 
number of samples is needed to identify all candidate cancer genes (Lawrence et al., 2014). 
To overcome the limitation of sample size, we compared the mutated genes with the Cancer 
Gene Census (Futreal et al., 2004). This approach identified two cancer genes mutated in 
more than 5% of the cohort, NF1 and MLL4, in addition to those nominated by MutSigCV.
In our cohort, 7 (8%) cases harbored inactivating mutations in the protein kinase cAMP-
dependent regulatory type I alpha gene (PRKAR1A) (Figure 1A). A homozygous deletion 
was found in three additional cases. While inactivating germline PRKAR1A mutations cause 
Carney complex and benign primary pigmented nodular adrenocortical disease (PPNAD) 
(Kirschner et al., 2000), malignant transformation has been reported in the adrenals of 
patients with this rare condition (Anselmo et al., 2012), and sporadic loss-of-function 
mutations in PRKAR1A have been found in adrenocortical adenomas and rare carcinomas 
(Bertherat et al., 2003). Interestingly, DNA sequencing of sporadic adrenocortical adenomas 
recently revealed a recurrent activating L206R mutation in the catalytic subunit of the 
cAMP-dependent protein kinase A (PKA) (PRKACA) (Beuschlein et al., 2014; Goh et al., 
2014). This mutation results in constitutive PKA activity by disrupting the interaction 
between PRKACA and the regulatory subunits of PKA including PRKAR1A (Calebiro et 
al., 2014; Goh et al., 2014). While we found no PRKACA mutations in our cohort, we 
observed decreased PRKAR1A expression and increased MEK and BRAF protein 
expression (Figure S1F and S1G) in mutant cases, suggesting a potential role for inhibition 
of the RAF-MEK-ERK cascade in treatment of some ACCs.
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We observed two frameshift mutations in ribosomal protein L22 (RPL22) and confirmed 
them by RNA sequencing (Figure 1A). We detected a third in-frame deletion mutation in a 
sample with heterozygous loss of RPL22, and homozygous loss of RPL22 in three ACCs. 
These findings suggest a role for somatic alteration of RPL22 in 7% of ACC, which has 
previously been related to MDM2-mediated p53 ubiquitination and degradation (Zhang and 
Lu, 2009).
Using two complementary analytical methods to detect fusion transcripts in mRNA-seq data 
(McPherson et al., 2011; Torres-Garcia et al., 2014), we identified 156 singleton but no 
recurrent gene fusion events in 48 of 78 (62%) tumors (range: 1–16) (Figure S1H and Table 
S1). Gene fusions occur at much lower frequencies than mutations and copy number variants 
(Yoshihara et al., 2015), and a larger cohort is needed to determine the frequency of fusions 
reported here. However, we did identify private in–frame fusions involving known cancer 
genes (Figure 1B). A highly expressed EXOSC10-MTOR fusion retained the mTOR 
catalytic domain and resulted in elevated levels of total and phosphorylated mTOR protein in 
this tumor (Figure S1I). The fusion point of a MLL-ATP5L fusion fell within the MLL 
breakpoint cluster region associated with acute myeloid leukemia (Krivtsov and Armstrong, 
2007). Both fusion cases lacked mutations in SMGs. A fusion involving the gene BRE, 
reported to promote tumor cell growth and adrenal neoplasia (Chan et al., 2005; Miao et al., 
2001), was identified in one tumor. While more data are required to ascertain their roles in 
ACC, these private fusions may represent functional transcripts.
Whole genome doubling is a common event in ACC
We assessed somatic copy number alterations (SCNAs) and loss of heterozygosity in 89 
tumors. Using GISTIC2 (Mermel et al., 2011), we identified recurrent focal amplifications 
of TERT (5p15.33), TERF2 (16q22.1), CDK4 (12q14.1) and CCNE1 (19q12) and deletions 
of RB1 (13q14.2), CDKN2A (9p21.2) and ZNRF3 (22q12.1) (q ≤ 0.01; Figure 1C and Table 
S1). A focal deletion peak around 4q34.3–4q35.1 centered on a long noncoding RNA 
LINC00290, which has been reported as a deletion target in pediatric ACCs and other 
cancers (Letouze et al., 2012; Zack et al., 2013). ZNRF3 homozygous deletions appeared in 
16% (n=14) of tumors assayed; by including non-silent mutations, 19.3% of ACCs harbored 
alterations in this gene. TERT and TERF2, two telomere maintenance related genes (Blasco, 
2005), were focally amplified in 15% and 7% of cases, respectively. TERT promoter hotspot 
mutations have been recently discovered in human cancers (Huang et al., 2013). We 
resequenced the TERT promoter region of all 91 tumors. In agreement with a recent study 
(Liu et al., 2014), we identified four cases with the C228T mutation, but no C250T 
mutations.
Arm-level copy number changes were frequent in ACC (Figure 2A and S2A). Clustering of 
89 tumors based on their arm-level alterations produced three groups with striking 
differences: chromosomal (n=54; 61%); noisy (n=27; 30%); and quiet (n=8; 9%) (Figure 
S2A). The chromosomal group showed the highest frequency of whole chromosome arm 
gains and losses. The noisy group was characterized by a significantly higher number of 
chromosomal breaks as well as frequent loss of 1p with 1q intact. Tumors in the quiet group 
had few large copy number alterations. Kaplan-Meier analysis demonstrated a significant 
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decrease in survival in the noisy group relative to the chromosomal and quiet subtypes, 
suggesting that this copy number phenotype is characteristic of aggressive disease (Figure 
S2A). To validate these subtypes, we analyzed an independent data set of ACC tumors 
(n=119) profiled on different versions of the Illumina BeadArray platform (Assie et al., 
2014). Based on the chromosome 1p/1q pattern, the noisy group and its survival association 
were recovered in this independent cohort (Figure S2B), suggesting that the group 
distinctions are robust. We did not observe copy number quiet ACC in the independent 
cohort.
We next determined tumor purity, ploidy and whole genome doubling (WGD) by integrating 
allelic copy number profiles and DNA mutation data using the previously validated 
ABSOLUTE algorithm (Carter et al., 2012). ACC samples were pure relative to other tumor 
types (tumor purity 0.82±0.15; Figure 2B). Consistently fractions of tumor infiltrated 
stromal cells estimated from gene expression signatures (Yoshihara et al., 2013) were low 
relative to a panel of 14 other cancer types (Figure S2C). Immune scores were lower in 
cortisol-secreting ACCs (p value=0.015), consistent with the suppression of T cell activity 
by glucocorticoids (Palacios and Sugawara, 1982). We found that hypodiploid karyotypes 
(ploidy ≤ 1.6) occurred more frequently in ACC than in eleven other tumor types (31% vs. 
1%; Figure 2B), a frequency that was only matched by chromophobe renal cell carcinoma. 
WGD occurred in 68% of the noisy subtype, 51% of the chromosomal subtype, and none of 
the diploid quiet subtype cases. We inferred the temporal order of somatic mutations for 
genes implicated in ACC based on variant allele fractions (VAF) and genotype (Figure 2C 
and S2D). Mutations in TP53 (n=7), MEN1 (n=3), RPL22 (n=2), and ZNRF3 (n=2) were 
predicted to have occurred prior to WGD. Only 4/9 CTNNB1 mutations were predicted to 
be pre-doubling, while three were post-doubling and the remaining two showed further 
reduced VAFs suggestive of subclonality. PRKAR1A mutations split evenly as having 
occurred before WGD, after WGD or being subclonal.
We observed that loss of heterozygosity (LOH) patterns were nearly identical between 
hypodiploid and hyperdiploid cases in the chromosomal group (rho=0.96, p value<10−5) 
(Figure S3A and S3B). We hypothesized that the undoubled chromosomal ACCs were 
precursors to the chromosomal ACC that underwent whole genome doubling. This model is 
corroborated by the difference in outcome and absolute copy number (Figure 3A, S3C and 
S3D). We did not find a survival difference between non-WGD and WGD noisy samples 
suggesting that additional factors may contribute to disease course or that we were 
underpowered to detect a statistically significant signal. Mutation density further 
corroborated the WGD hypothesis as the higher mutation frequency in WGD cases was 
eliminated after normalization by ploidy (Figure S3E).
We employed gene set enrichment analysis using gene expression data to uncover 
differences between WGD and non-WGD tumors. We identified significantly enhanced 
pathways in WGD tumors including telomere regulation, cell cycle regulation and DNA 
replication repair (Figure S3F and S3G). The identification of cell cycle regulation was 
verified by an independent algorithm, Evaluation of Dependency DifferentialitY (Jung and 
Kim, 2014), which detected enrichment of the PARKIN pathway (Figure S3F) including 
PARK2, a recently reported master regulator of G1/S cyclins (Gong et al., 2014).
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Amongst the telomere regulation pathway, TERT expression was significantly higher in the 
WGD group (FDR=0.05) (Figure 3B). Given the role of telomerase in maintaining telomere 
length (Blasco, 2005), we used spill over sequence generated by exome sequencing to infer 
telomere length of tumors and normal samples (Ding et al., 2014). Most tumors (73%) 
exhibited shorter telomeres than their matched normal samples (Figure 3C). WGD cases 
harbored shorter telomeres than non-WGD cases (Figure S3H). The association between 
WGD and TERT expression may suggest that increased TERT was required as a 
compensatory mechanism for telomere maintenance. Alternatively, TERT may have been 
non-functional with eroding telomeres as a consequence. This confirms previous 
observations that the majority of ACCs show telomerase activity, particularly in those with 
relatively short telomeres, while only a minority uses alternative telomere lengthening (ALT) 
as a telomere maintenance mechanism (Else et al., 2008). Telomere crisis is thought to drive 
tetraploidization (Davoli and de Lange, 2012) and may be directly associated with WGD 
events in these tumors. Similar to pediatric ACC and other cancers (Heaphy et al., 2011; 
Pinto et al., 2015), mutations in ATRX and DAXX (n=7) were associated with longer 
telomeres (p value= 5.4×10−5, Fisher’s exact test; Figure 3C). We did not find significant 
associations between telomere length and TERT promoter mutations or TERT amplification. 
Most cancers express TERT in the context of decreased telomere length (Maser and 
DePinho, 2002), suggesting that increased TERT maintains telomere homeostasis to a level 
that is sufficient for cancer cells to survive crisis. TERF2 was amplified in 7% of the cohort 
but similarly did not correlate with telomere length. TERF2 serves as an anchor protein of 
the shelterin complex which binds to telomeric DNA, but its direct involvement in telomere 
elongation has not been determined (Blasco, 2005). It has been documented that TERF2 
might have telomere-independent functions (Stewart and Weinberg, 2006), raising 
interesting hypotheses about its role in adrenal tumorigenesis.
Molecular classes of adrenocortical carcinoma are captured by DNA Methylation 
signatures
To derive a robust molecular classification, we used unsupervised clustering to analyze the 
genomic and transcriptomic datasets (Figure S4 and Figure S2A). This approach yielded 
four mRNA expression groups (Figure S4A–B), six microRNA expression groups (Figure 
S4C–K), three DNA methylation groups (Figure S4L), three copy number groups (Figure 
S2A) and three protein expression groups (Figure S4M–N). Except for microRNA based 
clustering, the individual cluster analyses all resulted in classifications with significant 
differences in outcome. These subtypes are summarized in Table S2 and characteristics of 
each molecular classification are described in detail in the Supplemental Information. We 
integrated the ACC subsets identified across the DNA copy number, DNA methylation, 
mRNA expression and miRNA expression platforms through a Cluster of Cluster (CoC) 
analysis (Figure 4). Combined, the molecular classifications converged into three CoC 
subtypes (Figure 4A and S4O). Transcriptome clustering in a non-overlapping ACC sample 
set has previously identified an aggressive C1A subtype and an indolent C1B subtype (de 
Reynies et al., 2009; Giordano et al., 2009). A comparison between CoC and C1A/C1B 
showed that the majority of CoC I were classified as C1B, while most CoC II and CoC III 
were predicted as C1A (Figure 4A). Pan-cancer pathway enrichment analyses showed 
significant up-regulation of genes in immune-mediated pathways in CoC I tumors and 
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mitotic pathways in CoC III tumors (Figure S4P). We compared the clinical outcome of the 
three CoC clusters. Disease progression rates of the three CoCs were 7%, 56%, and 96%, 
respectively. Survival analysis showed a dismal median event-free survival of eight months 
for CoC III (Figure 4B) while median event-free survival time was not reached in CoC I. 
CoC II was more heterogeneous in outcome with an event-free survival of 38 months. Stage 
III/IV tumors represented 25%, 47%, and 52% of CoC I, II, III, respectively, and stage I/II 
cases in CoC III showed MKI67 values in accordance with their grade classification (Figure 
5A).
While the CoC analysis showed that molecular data can determine outcome with high 
significance, implementing four parallel profiling platforms poses a clinical challenge. The 
four expression subtypes and three methylation subtypes rendered discriminative 
representations of each CoC group (Figure 4A), offering plausible routes for clinical 
implementation. Given the potential of the methylation platform to provide accurate data on 
formalin fixed, paraffin embedded tumor samples (de Ruijter et al., 2015; Thirlwell et al., 
2010), we derived a methylation signature consisting of 68 probes that were included in both 
Illumina Human Methylation 450K and 27K arrays and tested its performance. This 
signature robustly classified our cohort into three ACC survival groups with 92.4% accuracy 
(Table S2). Classification of 51 methylation profiles from an independent cohort (Assie et 
al., 2014) accurately validated the prognostic power of the methylation signature (Figure 
S4Q).
Integrated genomic landscape of ACC
We generated a genomic landscape of ACC by further integrating multimodal mutational 
and epigenetic data with the CoC three class solution (Figure 5A). In addition to DNA copy 
number and mutations, we assessed epigenetic silencing and germline mutations of 177 
manually selected genes (Table S3). We found 9 germline mutations, including two 
TP53R337H in two Brazilian patients, two MSH6, one MSH2 and one NF1R1534X mutations. 
The MSH6 and MSH2 mutations support recent observations that ACC is a Lynch 
syndrome-associated cancer (Raymond et al., 2013). The two TP53R337H mutated patients 
were younger than the rest of the cohort (23 and 30; median age of cohort: 49). We also 
found a single TINF2S245Y variant that is associated with dyskeratosis congenita. The likely 
benign variant APCE1317Q was observed in two cases (Rozek et al., 2006).
Collectively the genes altered most frequently by somatic mutations, DNA copy number 
alterations and epigenetic silencing were TP53 (21%), ZNRF3 (19%), CDKN2A (15%), 
CTNNB1 (16%), TERT (14%) and PRKAR1A (11%). The majority of gene alterations were 
either mutation or copy number change, except CDKN2A, which was targeted by both 
deletion and epigenetic silencing through promoter DNA methylation. Alterations of 
ZNRF3, CTNNB1, APC and MEN1 resulted in modification of the Wnt/β-catenin pathway 
in 41% of cases (Figure 5B). Wnt pathway activity, as measured by expression of canonical 
Wnt target genes, was increased in ACC with Wnt-pathway alterations relative to Wnt wild-
type samples (Figure S5A). Somatic alterations in TP53, CDKN2A, RB1, CDK4 and 
CCNE1 emphasize the importance of the p53 apoptosis/Rb1 cell cycle pathway, and were 
altered in 44.9% of the cases (Figure 5B). Finally, histone modification genes (MLL, MLL2, 
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and MLL4) and chromatin remodeling genes (ATRX and DAXX) were collectively altered 
in 22% of cases, suggesting a role for epigenetic deregulation in ACC tumorigenesis (Figure 
5C). Unsupervised HotNet2 analysis of protein-protein interaction network identified four 
significant subnetworks containing at least four genes (Figure S5B, p value<0.0001) 
(Leiserson et al., 2015). In addition to p53, Rb-cell cycle and Wnt-alteration subnetworks, 
HotNet2 showed a PKA network affecting 16 samples in total.
Combining somatic mutations, copy number alterations, and epigenetic modification, we 
found at least one alteration of potential driver genes in 69% of tumors (Figure 5A). The 
majority of CoC I tumors did not harbor a driver alteration that we could detect. We also 
examined the expression of IGF2 and an established proliferation marker MKI67. MKI67 
expression was lower in CoC I tumors, consistent with the indolent phenotype of this 
subtype. IGF2 expression was unanimously high independent of ACC classification. 
Expression of IGF2 was relatively high in 67 of 78 (86%) ACCs (cutoff log2(RSEM)=14 
determined by expression distribution), with no association to either promoter DNA 
methylation or genome rearrangement.
Based on existing clinical trials and FDA-approved drugs for cancers, we found 51 
potentially actionable alterations, including both mutations and copy number alterations, in 
22 ACCs using precision heuristics for interpreting the actionable landscape (PHIAL) (Van 
Allen et al., 2014), from cyclin-dependent kinases to DNA repair protein poly ADP-ribose 
polymerase (PARP) (Figure S5C and Table S3).
Pan-Cancer Analyses provide context to ACC
Pan-cancer analysis of genomic data has provided insights on a wide range of cancer related 
questions. In an attempt to understand the driving mechanisms of ACC, we grouped our 
cohort on the basis of recurrent cancer-driving alterations using OncoSign (Ciriello et al., 
2013). Our results broadly recapitulated the C class (OSC1–3, copy number driven) and M 
class (OSC 4–5, mutation driven) that have been described as a general trend across cancers 
(Ciriello et al., 2013) (Figure S6A).
The accumulation of somatic mutations in cancer is caused by mutational processes that can 
be deconvoluted as mutational signatures (Alexandrov et al., 2013). To examine mutational 
processes in ACC, we extracted 6 mutational signatures from 85 ACCs (mutation number ≥ 
10) and about 2,900 other cancers using non-negative matrix factorization (Figure S6B). We 
compared the six signatures with the 22 signatures from an independent study (Alexandrov 
et al., 2013). Signature 1 resembled the age and DNA mismatch repair deficiency signatures, 
all featuring C>T substitution in the CG context. Signature 2 resembled the smoking 
signature featuring C>A substitution in the CG context. Signature 5 resembled UV and 
APOBEC signatures featuring C>G, C>T, and C>T substitutions in the contexts of TC, CC 
and TC, respectively. We did not find an association between signatures and sample country 
of origin (p value=0.9, Fisher’s exact test). The majority of ACCs exhibited signatures 1, 2 
and 4 (Figure 6A). Signature 1 captured the majority of gastrointestinal cancers (stomach, 
esophageal, colorectal) but also four ACC with a relatively high mutation frequency, all of 
which harbored mutations in the DNA mismatch repair pathway (Figure 6B). One case with 
a germline MSH6 mutation but relatively modest mutation density (0.51 mutations/Mb) also 
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clustered with this signature. The smoking associated adenocarcinoma and squamous cell 
lung cancers in signature 2 also featured four high mutation frequency ACCs. Smoking has 
been listed as an ACC risk factor (Hsing et al., 1996). A set of Human papillomavirus 
(HPV)-driven cancers, including cervical, bladder and head and neck cancers, clustered 
together but did not capture any ACC. We analyzed RNA and exome sequencing data for 
microbial sequence reads (Chu et al., 2014) and identified human herpes virus sequences in 
nine exomes but not HPV sequence reads. De novo assembly of herpes virus sequences 
confirmed their presence but returned no evidence for viral genomic integration (Figure 
S6C).
Molecular correlates of ACC pathology and adrenocortical differentiation
We evaluated adrenocortical differentiation by using 25 genes with very high expression 
levels in the adult adrenal cortex and that are of importance for adrenal function, including 
steroidogenic enzymes, cholesterol transporters and their transcriptional regulator, SF1 
(NR5A1) (Figure S7A and Table S4). We derived a single metric, termed Adrenocortical 
Differentiation Score (ADS), to measure adrenocortical differentiation (Figure 7). Sorting 
the tumors according to their ADS values we observed that functional tumors showed higher 
ADS values, which did not correlate with Weiss histopathology score (p value=0.41, 
ANOVA). TP53 mutations were present across the spectrum of ADS values (p value=0.56, 
Fisher’s exact test), whereas Wnt-related mutations appeared to be enriched among tumors 
with higher ADS values (p value=0.0091, Fisher’s exact test). Not surprisingly, the two 
sarcomatoid tumors had the lowest ADS values with very low expression of NR5A1 and 
steroidogenic enzymes (Figure S7B). One such patient had elevated serum cortisol levels, 
suggesting a mixed histology in which a differentiated component expressed steroidogenic 
enzymes and an undifferentiated component did not. The other tumor was histologically 
mixed with separate components of usual and sarcomatoid ACC. We suggest that these 
sarcomatoid, NR5A1-negative tumors do indeed represent dedifferentiated ACCs, rather 
than retroperitoneal sarcomas.
DISCUSSION
As part of TCGA, we present an integrated molecular characterization of a large cohort of 
ACC. The tumors were derived from four continents and thus represent a near-global 
sampling of this disease. The data presented here represents a resource for future 
investigations to facilitate ACC research across myriad avenues, including via pan-cancer 
analysis.
Our study builds upon prior efforts on adult ACC from European (Assie et al., 2014) and 
North American patients (Juhlin et al., 2015), as well as pediatric ACC patients from North 
America and Brazil (Pinto et al., 2015). Using high quality multidimensional genomic data, 
we confirm many alterations as essential for ACC development and progression but also 
expand the somatic genetic landscape of ACC to nearly double the known ACC driver genes. 
The high frequency of PRKAR1A mutations expands the role of PKA signaling in ACC and 
is consistent with PRKACA somatic mutations being the founder lesion of benign adrenal 
tumor associated with endocrinopathies such as Cushing syndrome (Beuschlein et al., 2014). 
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By integrating data from multiple platforms we demonstrated the critical role of WGD. 
While WGD is common across cancer (Zack et al., 2013), an association between WGD and 
patient outcome has only been reported in ovarian cancer (Carter et al., 2012). The 
exceptional high level of tumor purity and the clear evidence that WGD is a marker of tumor 
progression make ACC a model disease for better understanding of the mechanisms that 
result in doubling and the molecular context needed to sustain it.
Weiss and colleagues (Weiss et al., 1989) first proposed that ACC consists of two pathologic 
classes that have different mitotic rates and distinct clinical outcomes. This proliferation-
based two-grade (low and high) system has been confirmed by several transcriptome studies 
(de Reynies et al., 2009; Giordano et al., 2009) and has been clinically implemented by 
some centers (Giordano, 2011). We confirmed the two-grade classification with mRNA-seq 
data and importantly, used multidimensional data to extend the molecular classification to 
three classes that have markedly distinct biological properties and significantly different 
patient outcomes. Clinical implementation of this three-class grading system using DNA 
methylation profiles could facilitate improved patient care, although additional translational 
efforts are needed for its implementation. Despite these uncertainties, our results represent 
an extensive ensemble of molecular ACC subtypes and thus are likely to be useful in 
directing future development of clinically applicable classifiers. Moreover, our results 
illustrate how molecular data, combined with traditional clinicopathologic assessment, might 
inform therapeutic decisions and lead to advances in patient outcomes. The diversity of 
genomic alterations, especially the significant copy number changes seen in the majority of 
ACC, suggests that combined inhibition of disease pathways, however challenging, likely 
holds the key to successful targeted therapy for ACC.
EXPERIMENTAL PROCEDURES
Tumor and normal samples were obtained from patients after informed consent and with 
approval from local Institutional Review Boards (RIB). Details on all contributing Centers 
and their IRB approval can be found in the Supplemental Information. DNA, RNA and 
protein were purified and distributed throughout the TCGA network. In total, 91 primary 
tumors with associated clinicopathologic data were assayed on at least one molecular 
profiling platform. Platforms included exome sequencing, mRNA sequencing, miRNA 
sequencing, SNP arrays, DNA methylation arrays, and reverse phase protein arrays. 
Mutation calling was performed by 5 independent callers, and a voting mechanism was used 
to generate the final mutation set. MutSigCV (version 1.4) was used to determine 
significantly mutated genes (Lawrence et al., 2013). GISTIC2.0 was used to identify 
recurrent deletion and amplification peaks(Mermel et al., 2011). Consensus clustering was 
used to derive miRNA, mRNA, methylation and protein subtypes. Tumor purity, ploidy and 
whole genome doubling were determined by ABSOLUTE (Carter et al., 2012). The data and 
analysis results can be explored through TCGA data portal (https://tcga-data.nci.nih.gov/
tcga/tcgaCancerDetails.jsp?diseaseType=ACC), the Broad Institute GDAC FireBrowse 
portal (http://firebrowse.org/?cohort=ACC), Memorial Sloan Kettering Cancer Center 
cBioPortal (http://www.cbioportal.org/public-portal/study.do?cancer_study_id=acc_tcga), 
Regulome Explorer (http://explorer.cancerregulome.org/all_pairs/?dataset=TCGA_ACC). 
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See also the Supplemental Experimental Procedures and the ACC publication page (https://
tcga-data.nci.nih.gov/docs/publications/acc_2016/).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SIGNIFICANCE
Adrenocortical carcinoma is a rare endocrine cancer with limited therapeutic options and 
overall poor outcome. We comprehensively analyzed 91 ACC specimens from four 
continents using state of the art genomic technologies and computational methods. In 
addition to identification of ACC driver genes, pathways and refined subtypes, our 
analysis revealed whole genome doubling (WGD) as a milestone in disease progression. 
Our findings suggest that ACC can serve as a model for how WGD influences disease 
progression. Our dataset is standardized with other TCGA studies, fully available at the 
TCGA Data Portal, and thus will serve as a valuable research resource.
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Highlights
• Standardized molecular data from 91 cases of adrenocortical carcinoma
• Driver genes including TP53,ZNFR3,CTNNB1, PRKAR1A,CCNE1 and TERF2
• Whole genome doubling event is a marker for ACC progression
• Three prognostic molecular subtypes captured by a DNA methylation signature
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Figure 1. Mutational driver genes in ACC
(A) Protein domain structure of the five significantly mutated genes with somatic mutations 
aligned. Functional domains and mutation types are indicated in different colors and shapes 
as shown in the legend. Arm, Armadillo domain; TAD, transcription-activation domain; 
DBD, DNA binding domain; TMD, tetramerisation domain; RIIa, regulatory subunit of type 
II PKA R-subunit. (B) Sporadic gene fusions that involve cancer genes. All exons are 
represented, with red and blue indicating high and low expression respectively. Lines linking 
two exons indicate the fusion positions. Protein domains are related to the exons below the 
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gene diagram. HRDC, helicase and RNase D C-terminal; PI3Kc, phosphoinositide 3-kinase, 
catalytic domain; ATH, AT-hook motif; PHD, plant homology domain; SET, Su(var)3–9, 
enhancer-of-zeste, trithorax; PP2Ac, protein phosphatase 2A homologues, catalytic domain. 
(C) Focal recurrent amplifications and deletions in ACCs with the number of genes spanned 
by the peak in parentheses. Red and blue indicate amplification and deletion, respectively. 
The x-axis at the bottom and top of the figure represents significance of amplification/
deletion per q-value. See also Figure S1 and Table S1.
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Figure 2. Landscape of DNA copy number alteration in ACC
(A) Three major copy number patterns in ACC. Unsupervised clustering divided the cohort 
(n=89) into quiet, chromosomal and noisy subtypes. (B) Pan-cancer purity and ploidy 
including ACC. Sample sizes are indicated on top. Average tumor purity is plotted as a grey 
line for each cancer type. The percentages of whole genome doubling and hypodiploidy 
(ploidy ≤1.6) are listed in red and blue, respectively. LUAD - lung adenocarcinoma; LUSC – 
lung squamous; HNSC – head and neck; KIRC – clear cell renal cell; BRCA – breast; 
BLCA – bladder; CRC – colorectal; THCA – thyroid papillary; UCEC – endometrial; GBM 
– glioblastoma; OV – ovarian; KICH – kidney chromophobe. (C) Purity adjusted variant 
allele fraction in genome doubled and undoubled tumors. Only tumors with high purity 
(≥0.8) and mutation density less than 5 were included. Cutoffs labeled in the figure are 
recognized as turning points in the density distributions of variant allele fractions. See also 
Figure S2.
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Figure 3. Comparison of WGD and non-WGD ACCs
(A) Event free survival of copy number subtypes and whole genome doubling groups. P 
value represents the statistical significance of event free survival differences between the five 
groups. (B) TERT expression in genome undoubled and doubled tumors. Boxplot shows 
median and interquartile range of TERT expressions, with whiskers extending to extreme 
values within 1.5 interquartile ranges from the upper and lower quartiles. Each dot 
corresponds to a tumor. (C) Telomere length was estimated using off-target exome 
sequencing data corrected for tumor purity and ploidy. Top panel shows TERT expression 
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with “x” representing missing values. TERT promoter C228T mutation (black), 
amplification (red) and TERF2 amplification (red) are noted in the second panel. The bottom 
panel represents ATRX and DAXX mutations in light blue and dark red, respectively. See 
also Figure S3.
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Figure 4. Cluster of clusters
(A) Cluster of clusters (CoCs) from four platforms (DNA copy number, black; mRNA 
expression, red; DNA methylation, blue; miRNA expression, purple) divided the cohort into 
3 groups. Presence or absence of membership for each sample is represented by black or 
light blue ticks, respectively. Sample parameters are aligned on top of the heatmap. White 
tick indicates data not available. (B) Event free survival of the 3 CoC groups. Pairwise log-
rank test p values are shown. See also Figure S4 and Table S2.
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Figure 5. Genomic landscape of ACC
(A) The ensemble of mutations, copy number alterations, methylations, subtypes and 
clinicopathological parameters. (B) Aggregated alterations of the p53/Rb pathway and the 
Wnt pathways. Activating and deactivating alterations are indicated in red and blue, 
respectively. (C) Mutations in epigenetic regulatory genes. See also Figure S5 and Table S3.
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Figure 6. Pan-cancer mutational signature analysis
(A) Distribution of the mutational signatures extracted from pan-cancer analysis in the ACC 
cohort. Signature 2 is enriched in the cluster of clusters groups 1 and 2. (B) Circular plot of 
the mutational signatures in ACC and approximately 2,900 tumor samples from other cancer 
types. The distance to the center represents coding mutation density. Three small 
illustrations highlight ACC, lung squamous cell carcinoma and colorectal cancer to 
demonstrate their similarities in the featured directions. See also Figure S6.
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Figure 7. Distribution of Adrenal Differentiation Score (ADS)
The 25-gene signature is shown in the expression heatmap. Adrenal cortex differentiation 
markers are listed on the left. Two sarcomatoid cases are indicated in red. See also Figure S7 
and Table S4.
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